188 related articles for article (PubMed ID: 35976603)
1. Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect.
Ichikawa S; Tsutsumi J; Sugimoto K; Yamakawa S
Adv Ther; 2022 Oct; 39(10):4779-4791. PubMed ID: 35976603
[TBL] [Abstract][Full Text] [Related]
2. Exploratory study on the relationship between urinary sodium/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study.
Katsuya T; Inobe Y; Uchiyama K; Nishikawa T; Hirano K; Kato M; Fukui T; Hatta T; Iwasaki A; Ishii H; Sugiura T; Taguchi T; Tanabe A; Sugimoto K; Shimosawa T;
Hypertens Res; 2024 Apr; 47(4):835-848. PubMed ID: 38212366
[TBL] [Abstract][Full Text] [Related]
3. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
Rakugi H; Ito S; Itoh H; Okuda Y; Yamakawa S
Hypertens Res; 2019 Dec; 42(12):1932-1941. PubMed ID: 31554937
[TBL] [Abstract][Full Text] [Related]
4. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).
Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
Hypertension; 2020 Jan; 75(1):51-58. PubMed ID: 31786983
[TBL] [Abstract][Full Text] [Related]
5. Association of Antihypertensive Effects of Esaxerenone with the Internal Sodium Balance in Dahl Salt-Sensitive Hypertensive Rats.
Hattori M; Rahman A; Kidoguchi S; Jahan N; Fujisawa Y; Morisawa N; Ohsaki H; Kobara H; Masaki T; Hossain A; Steeve A; Nishiyama A
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012182
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.
Ito S; Itoh H; Rakugi H; Okuda Y; Yamakawa S
J Hum Hypertens; 2019 Jul; 33(7):542-551. PubMed ID: 31113987
[TBL] [Abstract][Full Text] [Related]
7. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
Li L; Guan Y; Kobori H; Morishita A; Kobara H; Masaki T; Nakano D; Nishiyama A
Hypertens Res; 2019 Jun; 42(6):769-778. PubMed ID: 30587856
[TBL] [Abstract][Full Text] [Related]
8. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction.
Ito S; Itoh H; Rakugi H; Okuda Y; Iijima S
Hypertens Res; 2021 May; 44(5):489-497. PubMed ID: 33323991
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.
Satoh F; Ito S; Itoh H; Rakugi H; Shibata H; Ichihara A; Omura M; Takahashi K; Okuda Y; Iijima S
Hypertens Res; 2021 Apr; 44(4):464-472. PubMed ID: 33199881
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study.
Yamamoto E; Usuku H; Sueta D; Suzuki S; Nakamura T; Matsui K; Matsushita K; Iwasaki T; Sakaino N; Sakanashi T; Hirayama K; Kurokawa H; Kikuta K; Yamamoto N; Sato K; Tokitsu T; Taguchi T; Shiosakai K; Sugimoto K; Tsujita K;
Adv Ther; 2024 Mar; 41(3):1284-1303. PubMed ID: 38310194
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro
Yamakawa S; Homma T; Yamada M; Igawa Y; Yoshimura M
Nihon Yakurigaku Zasshi; 2020; 155(5):340-350. PubMed ID: 32879177
[TBL] [Abstract][Full Text] [Related]
12. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
Arai K; Morikawa Y; Ubukata N; Sugimoto K
Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH).
Motoki H; Inobe Y; Fukui T; Iwasaki A; Hiramitsu S; Koyama S; Masuda I; Sekimura N; Yamamoto K; Sato A; Komatsu M; Taguchi T; Shiosakai K; Sugimoto K; Kuwahara K
Adv Ther; 2023 Nov; 40(11):5055-5075. PubMed ID: 37733211
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE-HT study.
Kario K; Ohishi M; Katsuya T; Taguchi T; Tanabe A; Sugimoto K; Shimosawa T
J Clin Hypertens (Greenwich); 2023 Sep; 25(9):861-867. PubMed ID: 37551054
[TBL] [Abstract][Full Text] [Related]
15. Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.
Kario K; Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
Am J Hypertens; 2021 May; 34(5):540-551. PubMed ID: 33165570
[TBL] [Abstract][Full Text] [Related]
16. Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study.
Kario K; Nishizawa M; Kato M; Ishii H; Uchiyama K; Nagai M; Takahashi N; Asakura T; Shiraiwa T; Yoshida T; Kaneshiro M; Taguchi T; Shiosakai K; Sugimoto K
Hypertens Res; 2023 Jul; 46(7):1782-1794. PubMed ID: 37173430
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III Studies.
Ito S; Okuda Y; Sugimoto K
Adv Ther; 2023 Mar; 40(3):1242-1266. PubMed ID: 36662393
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study.
Uchida HA; Nakajima H; Hashimoto M; Nakamura A; Nunoue T; Murakami K; Hosoya T; Komoto K; Taguchi T; Akasaka T; Shiosakai K; Sugimoto K; Wada J;
Adv Ther; 2022 Nov; 39(11):5158-5175. PubMed ID: 36070133
[TBL] [Abstract][Full Text] [Related]
19. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
[TBL] [Abstract][Full Text] [Related]
20. The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial.
Okuda Y; Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Sawanobori T; Taguri M
Hypertens Res; 2023 Feb; 46(2):437-444. PubMed ID: 36100672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
